Compare ArcelorMittal SA (MT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Neurocrine Biosciences Inc — how do they compare? ArcelorMittal SA trades at $66.25 (market cap $50.01B), while Neurocrine Biosciences Inc trades at $179.87 (market cap $17.40B). The key difference: ArcelorMittal SA is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and ArcelorMittal SA pays a 0.91% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MT | NBIX | |
|---|---|---|
Market Cap | $50.01B | $17.40B |
Sector | Basic Materials | Health |
52-Week High | $71.65 | $180.55 |
52-Week Low | $30.39 | $123.10 |
Enterprise Value | $59.33B | $16.49B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
